Anti-GM1 antibodies are not associated with cerebral atrophy in patients with multiple sclerosis

Abstract

Objectives

The aim of this study was to correlate the brain atrophy with serum levels of anti-GM1 antibodies in patients with relapsing–remitting multiple sclerosis (RRMS).

Methods

Plasma sample from 52 patients with RRMS and 65 healthy controls were examined for anti-GM1 antibodies. Patients with RRMS underwent to MRI study with automated method called SIENAX that calculated an estimate of gray matter (GM^V) and white matter (WM^V) volumes.

Results

The percentage of RRMS patients with increased anti-GM1 was 37.8%. Elevated levels of anti-GM1 antibodies did not correlate with brain atrophy.

Conclusions

Anti-GM1 antibodies do not represent a marker of axonal damage in patients with RRMS.

Keywords

anti-GM1 relapsing–remitting multiple sclerosis

Get full access to this article

View all access options for this article.

References

1 Acarìn N Rìo J Fernàndez AL . Different antiganglioside antibodies pattern between relapsing remitting and progressive multiple sclerosis. Acta Neurol Scand 1996; 93: 99–103.

2 Sadatipour BT Greer JM Pender MP . Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann Neurol 1998; 44: 980–983.

3 Tedeschi G Lavorgna L Russo P . Brain atrophy and lesion load in a large population of patients with multiple sclerosis. Neurology 2005; 65: 280–285.

4 McDonald WI Compston A Edan G . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121–127.

5 Zappia M Crescibene L Bosco D . Anti-GM1 ganglioside antibodies in Parkinson’s disease. Acta Neurol Scand 2002; 106: 54–57.

6 Smith SM Zhang Y Jenkinson M . Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002; 17: 479–489.

7 Giovannoni G Morris PR Keir G . Circulating antiganglioside antibodies are not associated with the development of progressive disease or cerebral atrophy in patients with multiple sclerosis. Ann Neurol 2000; 47: 684–685.